Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population.
• Fenoldopam (a medicine that rapidly widens and relaxes blood vessels) probably reduces the risk of developing acute kidney injury (AKI) (a condition where the kidneys suddenly lose their ability to ...
short-term (called acute kidney injury or AKI), which is reversible with timely treatment; and long-term (called chronic kidney disease or CKD), which is usually irreversible. When CKD occurs ...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...
REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to ...